LH Laboratory Corp. Of America

Laboratory Corp. of America Holdings is a clinical laboratory company. The firm engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the following segments: LabCorp Diagnostics and Covance Drug Development. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment provides drug development solutions to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.

Company profile

David King
Fiscal year end
Former names
IRS number

LH stock data



25 Feb 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Apr 21 Kirchgraber Paul R Common Stock Payment of exercise Dispose F No No 252.67 452 114.21K 10,344
3 Apr 21 Kirchgraber Paul R Common Stock Option exercise Aquire M No No 0 1,010 0 10,796
3 Apr 21 Kirchgraber Paul R RSU Common Stock Option exercise Dispose M No No 0 1,010 0 6,781
30 Mar 21 van der Vaart Sandra D Common Stock Sell Dispose S No Yes 251.88 812 204.53K 5,237.042
30 Mar 21 Schroeder Mark S Common Stock Sell Dispose S No Yes 251.88 667 168K 5,006.379
27 Mar 21 van der Vaart Sandra D Common Stock Payment of exercise Dispose F No No 251.58 687 172.84K 6,049.042
27 Mar 21 van der Vaart Sandra D Common Stock Grant Aquire A No No 0 2,310 0 6,736.042
27 Mar 21 Schroeder Mark S Common Stock Payment of exercise Dispose F No No 251.58 1,079 271.45K 5,673.379
27 Mar 21 Schroeder Mark S Common Stock Grant Aquire A No No 0 2,413 0 6,752.379

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

88.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 869 779 +11.6%
Opened positions 142 93 +52.7%
Closed positions 52 78 -33.3%
Increased positions 302 234 +29.1%
Reduced positions 286 312 -8.3%
13F shares
Current Prev Q Change
Total value 17.61B 16.22B +8.6%
Total shares 86.62M 86.17M +0.5%
Total puts 396.1K 555.9K -28.7%
Total calls 486.7K 363.3K +34.0%
Total put/call ratio 0.8 1.5 -46.8%
Largest owners
Shares Value Change
Vanguard 10.41M $2.12B -1.2%
BLK Blackrock 7.83M $1.59B -0.0%
STT State Street 4.07M $827.53M -2.3%
Wellington Management 2.74M $557.35M +10.2%
Nordea Investment Management Ab 1.9M $386.97M +7.5%
BEN Franklin Resources 1.84M $374.8M -29.3%
FMR 1.7M $346.52M +1.7%
Geode Capital Management 1.63M $330.79M +4.9%
BAC Bank Of America 1.44M $293.1M -6.3%
Lazard Asset Management 1.43M $290.4M +1.4%
Largest transactions
Shares Bought/sold Change
Norges Bank 909.99K +909.99K NEW
Jana Partners 811.66K +811.66K NEW
BEN Franklin Resources 1.84M -763.74K -29.3%
Melvin Capital Management 865K -763.01K -46.9%
Veritas Investment Partners 746.76K +746.76K NEW
Veritas Investment Management 0 -721.11K EXIT
Boston Partners 664.83K -544.17K -45.0%
Assenagon Asset Management 500.45K +500.45K NEW
Eminence Capital 614.43K +465.55K +312.7%
Massachusetts Financial Services 919.08K +443.74K +93.4%

Financial report summary

  • Item 1A. Risk Factors
  • The effects of the outbreak of the COVID-19 pandemic could have material adverse impacts on the Company’s business, results of operations, cash flows, and financial position.
  • If the Company does not respond appropriately to the ongoing COVID-19 pandemic, or if the Company’s customers do not perceive its response to be adequate, the Company could suffer damage to its reputation, which could adversely affect its business.
  • The ongoing COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption that could have an adverse impact on the Company’s financial position.
  • Risks Related to Regulatory and Compliance Matters
  • Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company’s reputation with customers and have a material adverse effect upon the Company’s business.
  • The Company's international operations could subject it to additional risks and expenses that could adversely impact the business or results of operations.
  • Expanded international operations may increase the Company’s exposure to liabilities under the anti-corruption laws.
  • Failure to comply with the regulations of pharmaceutical and medical device regulatory agencies, such as the FDA, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (U.K.), the European Medicines Agency, the National Medical Products Administration in China (NMPA), and the Pharmaceuticals and Medical Devices Agency in Japan, could result in sanctions and/or remedies against DD and have a material adverse effect upon the Company.
  • Animal populations may suffer diseases that can damage DD's inventory, harm its reputation, or result in other liability.
  • Failure to conduct animal research in compliance with animal welfare laws and regulations could result in sanctions and/or remedies against DD and have a material adverse effect upon the Company.
  • U.S. FDA regulation of diagnostic products and increased FDA regulation of laboratory-developed tests (LDTs) could result in increased costs and the imposition of fines or penalties, and could have a material adverse effect upon the Company’s business.
  • Risks Related to the Company's Business
  • General or macro-economic factors in the U.S. and globally may have a material adverse effect upon the Company, and a significant deterioration in the economy could negatively impact testing volumes, drug development services,
  • cash collections and the availability of credit.
  • Healthcare reform and changes to related products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an increase in capitated reimbursement mechanisms and evolving delivery models, could have a material adverse effect on the Company's revenues, profitability and cash flow.
  • Changes in government regulation or in practices relating to the biopharmaceutical industry could decrease the need for certain services that DD provides.
  • Operations may be disrupted and adversely impacted by the effects of adverse weather, other natural disasters, geopolitical events, public health crises, and other events outside of the Company's control.
  • Changes or disruption in services or supplies provided by third parties, including transportation, could adversely affect the Company’s business.
  • A failure to identify and successfully close and integrate strategic acquisition targets could have a material adverse effect on the Company's business objectives and its revenues and profitability.
  • Continued and increased consolidation of MCOs, biopharmaceutical companies, health systems, physicians and other customers could adversely affect the Company's business.
  • Unproductive labor environments, union strikes, work stoppages, Works Council negotiations, or failure to comply with labor or employment laws could adversely affect the Company's operations and have a material adverse effect upon the Company's business.
  • Global economic conditions and government and regulatory changes, including, but not limited to, the U.K.'s exit from the European Union (EU) could adversely impact the Company’s business and results of operations.
  • The Company bears financial risk for contracts that, including for reasons beyond the Company's control, may be underpriced, subject to cost overruns, delayed, or terminated or reduced in scope.
  • A significant increase in Dx's or DD's days sales outstanding could have an adverse effect on the Company’s business, including its cash flow, by increasing its bad debt or decreasing its cash flow.
  • DD’s revenues depend on the biopharmaceutical industry.
  • Foreign currency exchange fluctuations could have an adverse effect on the Company’s business.
  • The Company’s uses of financial instruments to limit its exposure to interest rate and currency fluctuations could expose it to risks and financial losses that may adversely affect the Company’s financial condition, liquidity and results of operations.
  • The Company’s level of indebtedness could adversely affect the Company’s liquidity, results of operations and business.
  • The Company's quarterly operating results may vary.
  • Risks Related to Technology and Cybersecurity
  • Failure to maintain the security of customer-related information or compliance with security requirements could damage the Company’s reputation with customers, cause it to incur substantial additional costs and become subject to litigation and enforcement actions.
  • Failure in the Company’s information technology systems or delays or failures in the development and implementation of updates or enhancements to those systems could significantly increase testing turnaround time or delay billing processes and otherwise disrupt the Company’s operations or customer relationships.
  • Hardware and software failures, delays in the operation of computer and communications systems, the failure to implement new systems or system enhancements to existing systems, and cybersecurity breaches may harm the Company.
  • Security breaches and unauthorized access to the Company's or its customers’ data could harm the Company’s reputation and adversely affect its business.
  • Risks Related to Legal Matters
  • The failure to successfully obtain, maintain and enforce intellectual property rights and defend against challenges to the Company’s intellectual property rights could adversely affect the Company.
  • Changes in tax laws and regulations or the interpretation of such may have a significant impact on the financial position, results of operations and cash flows of the Company.
  • Contract research services in the drug development industry create liability risks.
Content analysis
H.S. sophomore Bad
New words: acutely, advocacy, antibody, attended, ballot, Bermejo, car, cascading, casual, CDC, CDIO, Chancery, characterization, Charitable, chemotherapy, CHRO, cleaning, Colorado, confident, Congressional, context, covenant, CPPA, CPRA, craft, DD, Delinquent, dental, disinfection, distancing, donating, drop, dually, duty, dynamic, EMEA, encourage, equitable, EUA, Eugenio, evenly, extract, fewer, fight, flattened, flu, front, fuel, Gender, geography, geopolitical, gradual, great, half, headcount, healthy, heat, heightened, hinder, hygiene, impossible, inactive, inquiry, Jose, League, left, logo, magnitude, maximize, maximizing, mentoring, NAV, NPRM, oral, overseen, Pacific, paramount, PCR, perception, Peterson, petition, pivotal, polymerase, postponed, PPE, preserve, prioritization, prioritize, proper, Raymond, reaction, rebranding, recommended, Red, registry, reinstated, reinstituted, remit, remote, remotely, repository, retail, retrieve, revamped, reward, RNA, run, sanitation, sequestration, shorten, side, signal, speak, split, spread, steadily, steady, subsidy, susceptible, sweeping, tandem, tangible, Tecum, threat, throughput, tilted, tough, tradename, turmoil, turnover, UK, unavailable, underserved, unduly, unforeseen, unmet, unpaid, unplanned, untimely, Urban, vii, viii, vision, vital, won
Removed: absorption, acceptance, accomplished, accountant, accredited, AccuDraw, actuarially, ACWI, adherence, adrenal, advancement, advice, afternoon, aggregation, Alert, allergy, analytic, announcement, antianxiety, approximate, architecture, arguing, array, assay, autism, avoid, backstop, Belgium, benchmark, bioavailability, biochemical, biology, biomarker, biometric, biorepository, biostatistical, bleeding, Blue, BML, body, bone, calendar, capture, cardiac, caution, Caymen, CDD, cervical, checked, child, Chiltern, choice, cholesterol, choose, chromosomal, clarified, clinically, CMBP, collect, College, colon, Combinable, combining, commensurate, committing, Commodity, compatible, complicate, complicated, concurrent, configurable, congenital, connect, connected, consolidate, contextual, contextualized, Continual, continuum, correct, courier, cumbersome, curtailment, cystic, cytogenetic, cytologic, cytology, david, declaratory, deeply, demonstrably, deployed, designing, dianon, disclosed, disproportionately, Dow, drain, Duke, earn, earnout, easily, Eastern, edit, element, email, emerge, emphasized, endocrine, endpoint, essentially, estimator, etiology, evidenced, examination, Excellence, exclusive, excretion, existed, exome, expedite, expensive, exploratory, exploring, expressed, ExpressTM, father, feature, featuring, fetal, financially, Florence, fluorescence, forecasting, forefront, formation, formed, freeze, FSP, functionality, gene, generating, generation, Geneva, genital, GenoSure, genotyping, GMP, graphical, Greenfield, GSS, guiding, harmonizing, headquartered, hemophilia, histologic, historic, host, HPV, hundred, hybridization, hyperplasia, hypogonadal, IHC, illicit, imaging, immune, immunohistochemistry, immunological, immunology, incorrect, Indiana, individually, infertility, insight, insurer, intake, interpret, invitation, IRT, Japanese, judgmental, king, LabLink, largely, launching, LCD, legacy, leukemia, leukocyte, liable, lifesaving, lifetime, LinkTM, lipid, load, lowering, lung, makeup, manager, manually, maternal, MaterniT, medication, men, merged, message, metabolic, metabolism, metabolite, microarray, MINE, miscarriage, misclassified, missing, mitigating, mock, modification, molecule, mother, Mount, MSCI, multinational, multiplex, Mutual, navigate, NEC, NGS, NIPT, nonproprietary, nonqualified, noting, NuSwab, observational, occurrence, omniseq, optimize, optimized, organ, outlining, overcame, overnight, PAML, parallel, parent, path, pathologist, PayerTM, Pennsylvania, PEP, permission, personalized, PharmAcuity, PhenoSense, PhenoSenseGT, phenotyping, phlebotomist, picked, PK, planning, plasma, player, polymorphism, portal, postnatal, practicing, practitioner, PreCheck, PreCheckTM, prenatal, prescribed, proactive, produce, producing, programmatic, programmed, programming, promoting, proposition, protocol, provisional, Pte, PULSE, query, question, quicker, radiolabeled, randomization, rationalization, receiving, reclassify, reconstruction, recording, rectify, reflecting, REIT, reliance, remanded, remittance, resistance, resolve, retardation, revaluation, rich, rigor, room, round, Russell, safeguarding, samuel, SARL, scalability, scalable, scanning, scientifically, screen, screening, sequencing, sequential, SERP, serum, Shanghai, shell, Shield, shifted, signature, simultaneously, Sinai, Singapore, situ, smart, SNP, solution, somatic, sourced, spanning, specialist, spectrometry, spectroscopy, standardize, stature, steroid, store, strain, stratification, streamline, streamlining, stroke, subscribe, substantive, subtle, sum, supplementary, supplementing, suspect, Switzerland, syndrome, tailored, TCPA, telemedicine, Tennessee, testosterone, text, therapy, thrombin, thrombotic, tissue, Tokyo, tool, Touch, tracking, tract, trailing, translational, transplant, treat, trebling, trending, Trofile, tumor, UBS, unaudited, undergone, underinsured, undiagnosed, university, unparalleled, unprecedented, unsolicited, unusual, validated, validation, verification, Version, view, viewed, viewing, viral, Virginia, visibility, visit, visualization, vivo, voluntarily, voluntary, wearable, web, West, widespread, win, workflow, writing, Xcellerate